Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results-Reference-Cited by-同舟云学术

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results

Published:2017-02-07 Issue:2 Volume:12 Page:e0170395
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Link Jenny,Ramanujam Ryan,Auer Michael,Ryner Malin,Hässler Signe,Bachelet Delphine,Mbogning Cyprien,Warnke Clemens,Buck Dorothea,Hyldgaard Jensen Poul Erik,Sievers Claudia,Ingenhoven Kathleen,Fissolo Nicolas,Lindberg Raija,Grummel Verena,Donnellan Naoimh,Comabella Manuel,Montalban Xavier,Kieseier Bernd,Soelberg Sørensen Per,Hartung Hans-Peter,Derfuss Tobias,Lawton Andy,Sikkema Dan,Pallardy Marc,Hemmer Bernhard,Deisenhammer Florian,Broët Philippe,Dönnes Pierre,Davidson Julie,Fogdell-Hahn Anna,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference42 articles.

1. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS;Neurology,2001

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;Neurology,1993

3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG);LD Jacobs;Ann Neurol,1996

4. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes;F Deisenhammer;CNS Drugs,2009

5. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis;J Link;PLoS One,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rigid linker peptides improve the stability and anti‐inflammation effect of human serum albumin and α‐melanocyte‐stimulating hormone fusion proteins;Biotechnology Journal;2024-03

2. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial;Expert Opinion on Biological Therapy;2023-12-02

3. Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis;Journal of Neuroimmunology;2022-09

4. Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta;Multiple Sclerosis and Related Disorders;2022-07

5. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19